Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178371 | 0.97 | CYP2C19 (0.54) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL15237486 | 0.97 | CYP2C19 (0.54) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6908133 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6914861 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6918554 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6913148 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6909533 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6914937 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6916767 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA | |
| SCHEMBL6914857 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP1A2ALDH1A1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967199-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-22 | — | — | US | claimed |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | JOHNSON SIGMONG G (US) | 2003-10-30 | — | — | US | claimed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-6511980-B2 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-28 | — | — | US | claimed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119730854-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6511980-B2 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-0417760-A2 | Phenylalkanoyl substituted imidazo[4,5-c] pyridines | G.D. Searle & Co. (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4988707-A | Platelet activating factor, antiinflammatory agents, cardiovascular disorders and treatment of asthma | G. D. SEARLE & CO. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4536594-A | Process for the preparation of beta-disubstituted monocarboxylic acids | ELF FRANCE (FR) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE7A | CYP2C19 1350/4885CYP1A2 511/4885ALDH1A1 1240/4885 |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | CYP2C19 585/4885CYP1A2 1030/4885ALDH1A1 2113/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | CYP2C19 1489/4885CYP1A2 380/4885ALDH1A1 989/4885 |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | CYP2C19 440/4885CYP1A2 596/4885ALDH1A1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.